WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025 financial results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will also host a virtual Investor Day the same day at 10:30 a.m. ET. In addition to discussing third quarter 2025 financial results, the Investor Day will feature: An in-dept ...

Core Insights - Arcutis Biotherapeutics, Inc. announced that ZORYVE® (roflumilast) cream 0.15% received a strong recommendation from the American Academy of Dermatology (AAD) for managing adult atopic dermatitis (AD) [1][2] - The recommendation emphasizes ZORYVE's efficacy in improving pruritus and disease severity, along with its favorable tolerability and low treatment discontinuation rates [1][2] - ZORYVE is recognized as an effective, non-steroid option for daily management of mild to moderate AD in adults and pediatric patients aged 6 years and older [1][2] Company Overview - Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on innovations in immuno-dermatology [1][14] - The company has developed a portfolio of advanced targeted topicals approved for treating major inflammatory skin diseases, including AD, seborrheic dermatitis, and plaque psoriasis [5][14] - ZORYVE is the first FDA-approved branded topical phosphodiesterase-4 (PDE4) inhibitor indicated for these conditions [7][10] Product Information - ZORYVE cream 0.15% is specifically indicated for the topical treatment of mild to moderate AD in patients aged 6 years and older [10] - The product is part of a broader line that includes ZORYVE cream 0.3% and ZORYVE foam 0.3%, which are approved for plaque psoriasis and seborrheic dermatitis [6][9] - ZORYVE has been recognized for its effectiveness, receiving awards such as Glamour's Beauty and Wellness Award for "Eczema Product" in 2024 [6] Market Context - Atopic dermatitis affects approximately 16.5 million adults in the United States, highlighting a significant market opportunity for effective treatments [4][7] - The AAD's focused guideline update incorporates newly FDA-approved therapies, ensuring that healthcare professionals have access to the latest evidence-based recommendations for managing chronic conditions like AD [2][7]